Columbia, MD – (October 25, 2013) – ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of surgical and wound management products, today announced that it has broken ground on the expansion of its manufacturing facility in Lafayette, Indiana to support the Company’s current and anticipated growth.
The 14,000 square-foot addition to the current building will increase scalability and efficiency of ACell’s day-to-day operations and is expected to be completed in late 2014. With the expansion, the total manufacturing space will exceed 42,000 square feet.
“The significant growth of our business driven by continued physician adoption of MatriStem® has driven us to expand capacity at our Lafayette facility by roughly 50%,” said Rodney Bosley, ACell President and Chief Operating Officer. “Our Indiana facility is currently capable of producing all of our 510(k) cleared products from raw material processing through final packaging. This expansion will provide us with additional end-to-end manufacturing capabilities that we believe will support our growth for several years to come.”
ACell manufactures its MatriStem products in facilities located in Lafayette, Indiana and Columbia, Maryland using a complex and highly specialized process, requiring precision and expertise to address various technical, engineering and regulatory challenges. The Lafayette facility processes all of the material used in MatriStem products and manufactures the majority of ACell’s products.
“As an integral part of the Lafayette community, ACell offers an opportunity to help stimulate the local economy, and we are proud to support the Company as they expand their facility with the goal of transforming the standard of medical care and improving the quality of life of patients who are treated with their devices,” said City of Lafayette Mayor Tony Roswarski.
ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. Its patented MatriStem ECM medical devices maintain and support a healing environment through constructive remodeling and are available in particle and sheet forms for the treatment of acute wounds and use in various surgical procedures. For more information, visit www.acell.com.
ACell, Inc. is a leading developer, manufacturer and marketer of next-generation regenerative medicine products. Its products are cleared for a variety of indications and are marketed under the brand name “MatriStem.” A privately held Company, Acell produces MatriStem in its manufacturing facilities and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.
MatriStem Products consist of porcine-derived extracellular matrix (ECM) that maintain and support a healing environment through constructive remodeling, and are available in particle and sheet forms by prescription only. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. Refer to IFU supplied with each device for indications, contraindications, and precautions.Return to News